Earnings Releases·Nov 9, 2026, 7:08 AM ET

Ocular Therapeutix — Third Quarter 2026 Earnings Summary

Total net revenue declined to $12.9 million from $14.5 million in the prior year period, while net loss widened to $94.8 million ($0.42 per share) from $69.4 million ($0.38 per share) due to increased R&D, selling, and administrative expenses.
The company plans to submit the AXPAXLI NDA for wet AMD in Q4 2026 under the 505(b)(2) pathway, with cash reserves of $530.6 million projected to fund operations and debt service through 2028.
Clinical progress includes the SOL-R trial completion of randomization and a primary endpoint shift to Week 40 for Q1 2028 results, while the SOL-1 trial previously demonstrated superiority to aflibercept at Week 52.
Strategic updates include the appointment of Riad Sherif, MD, to the Board of Directors and the acceleration of commercial readiness activities in anticipation of a potential U.S. launch.